Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed Pharmaceuticals has announced a $36.9 million strategic investment in Alpha Tau Medical (Nasdaq: DRTS), acquiring approximately 14.1 million ordinary shares at $2.612 per share through a registered direct offering.
The partnership includes a three-year service agreement where Oramed will provide Alpha Tau with investor outreach, strategic guidance, and capital markets expertise. The collaboration unites two therapeutic delivery pioneers, combining Oramed's oral drug delivery platform with Alpha Tau's Alpha DaRT® alpha-radiation cancer therapy technology.
As part of the deal, Oramed will appoint two directors to Alpha Tau's Board. The investment aims to support Alpha Tau's ongoing developments, including:
- US clinical trials across four indications
- Manufacturing scale-up initiatives
- Commercialization efforts
- Expansion into trials for multiple internal organs
Oramed Pharmaceuticals ha annunciato un investimento strategico di 36,9 milioni di dollari in Alpha Tau Medical (Nasdaq: DRTS), acquisendo circa 14,1 milioni di azioni ordinarie a 2,612 dollari per azione tramite un'offerta diretta registrata.
La partnership prevede un accordo di servizio triennale in cui Oramed fornirà ad Alpha Tau supporto per l'engagement con gli investitori, consulenza strategica ed esperienza nei mercati finanziari. La collaborazione unisce due pionieri nelle terapie di somministrazione, combinando la piattaforma orale di Oramed con la tecnologia di terapia al radiamento alfa Alpha DaRT® di Alpha Tau per il trattamento del cancro.
Come parte dell’accordo, Oramed nominerà due membri nel consiglio di amministrazione di Alpha Tau. L’investimento ha l’obiettivo di sostenere gli sviluppi in corso di Alpha Tau, tra cui:
- trial clinici negli USA su quattro indicazioni
- iniziative di ampliamento della produzione
- attività di commercializzazione
- espansione verso studi clinici su più organi interni
Oramed Pharmaceuticals ha anunciado una inversión estratégica de 36,9 millones de dólares en Alpha Tau Medical (Nasdaq: DRTS), adquiriendo aproximadamente 14,1 millones de acciones ordinarias a 2,612 dólares por acción mediante una oferta directa registrada.
La colaboración incluye un acuerdo de servicio por tres años en el que Oramed brindará a Alpha Tau apoyo en la relación con inversores, orientación estratégica y experiencia en mercados de capitales. La alianza une a dos pioneros en terapias de administración, combinando la plataforma oral de Oramed con la tecnología de terapia contra el cáncer por radiación alfa Alpha DaRT® de Alpha Tau.
Como parte del acuerdo, Oramed designará a dos directores para el consejo de administración de Alpha Tau. La inversión tiene como objetivo apoyar los desarrollos en curso de Alpha Tau, que incluyen:
- ensayos clínicos en EE. UU. para cuatro indicaciones
- iniciativas de ampliación de la producción
- esfuerzos de comercialización
- expansión hacia ensayos en múltiples órganos internos
Oramed Pharmaceuticals가 Alpha Tau Medical(나스닥: DRTS)에 3,690만 달러의 전략적 투자를 발표하며, 등록 직접 공모를 통해 주당 2.612달러에 약 1,410만 주의 보통주를 취득했습니다.
이번 파트너십에는 3년간의 서비스 계약이 포함되어 있으며, Oramed는 Alpha Tau에 투자자 소통, 전략적 조언 및 자본 시장 전문 지식을 제공할 예정입니다. 이번 협력은 두 치료 전달 분야의 선구자를 결합하여 Oramed의 경구 약물 전달 플랫폼과 Alpha Tau의 알파 방사선 암 치료 기술인 Alpha DaRT®를 통합합니다.
계약의 일환으로 Oramed는 Alpha Tau 이사회에 두 명의 이사를 임명할 예정입니다. 이번 투자는 Alpha Tau의 진행 중인 개발을 지원하는 것을 목표로 하며, 주요 내용은 다음과 같습니다:
- 미국 내 4가지 적응증에 대한 임상 시험
- 제조 규모 확대 계획
- 상업화 노력
- 다양한 내부 장기 대상 시험 확대
Oramed Pharmaceuticals a annoncé un investissement stratégique de 36,9 millions de dollars dans Alpha Tau Medical (Nasdaq : DRTS), acquérant environ 14,1 millions d’actions ordinaires à 2,612 dollars par action via une offre directe enregistrée.
Le partenariat inclut un accord de service de trois ans dans lequel Oramed fournira à Alpha Tau un soutien pour la relation avec les investisseurs, des conseils stratégiques et une expertise des marchés financiers. Cette collaboration réunit deux pionniers de la délivrance thérapeutique, combinant la plateforme orale d’Oramed avec la technologie de thérapie par radiation alpha Alpha DaRT® d’Alpha Tau pour le traitement du cancer.
Dans le cadre de l’accord, Oramed nommera deux administrateurs au conseil d’administration d’Alpha Tau. L’investissement vise à soutenir les développements en cours d’Alpha Tau, notamment :
- des essais cliniques aux États-Unis sur quatre indications
- des initiatives d’augmentation de la production
- des efforts de commercialisation
- l’expansion des essais à plusieurs organes internes
Oramed Pharmaceuticals hat eine strategische Investition von 36,9 Millionen US-Dollar in Alpha Tau Medical (Nasdaq: DRTS) bekanntgegeben und dabei rund 14,1 Millionen Stammaktien zu je 2,612 US-Dollar im Rahmen eines registrierten Direktangebots erworben.
Die Partnerschaft umfasst eine dreijährige Servicevereinbarung, bei der Oramed Alpha Tau Investor Relations, strategische Beratung und Kapitalmarktexpertise bereitstellt. Die Zusammenarbeit vereint zwei Pioniere der therapeutischen Verabreichung, indem Orameds orale Wirkstoffabgabeplattform mit Alpha Taus Alpha DaRT® Alpha-Strahlen-Krebstherapie-Technologie kombiniert wird.
Im Rahmen der Vereinbarung wird Oramed zwei Direktoren in den Vorstand von Alpha Tau berufen. Die Investition soll die laufenden Entwicklungen von Alpha Tau unterstützen, darunter:
- klinische Studien in den USA zu vier Indikationen
- Initiativen zur Produktionsskalierung
- Kommerzialisierungsmaßnahmen
- Erweiterung der Studien auf mehrere innere Organe
- Substantial $36.9M capital injection strengthens Alpha Tau's financial position
- Strategic partnership provides access to capital markets expertise
- Expansion of clinical trials across four US indications
- Manufacturing capacity expansion and pre-commercial preparations underway
- Significant share dilution for existing DRTS shareholders due to 14.1M new shares issuance
Insights
Oramed's $36.8M strategic investment in Alpha Tau provides capital, expertise, and board seats while diversifying Oramed's portfolio into oncology.
Oramed's investment in Alpha Tau Medical represents a significant strategic transaction with multiple dimensions beyond capital infusion. Through a registered direct offering, Oramed's affiliate purchased 14.1 million Alpha Tau shares at $2.612 per share, totaling approximately
The governance aspect is particularly noteworthy, as Oramed will appoint two directors to Alpha Tau's Board, giving them meaningful influence over strategic direction. This represents a thoughtful alignment between companies with complementary technological approaches to therapeutic delivery - Oramed's oral delivery platform for injectable medications and Alpha Tau's precision radiation delivery for cancer treatment.
For Oramed, this investment diversifies their portfolio beyond oral drug delivery into the oncology space through a non-competitive, yet conceptually aligned technology. For Alpha Tau, the partnership brings both capital and commercialization expertise at a pivotal time as they expand their clinical trials and manufacturing capabilities. This capital infusion supports Alpha Tau's parallel development across four U.S. clinical trials in different indications while building commercial infrastructure.
Partnership accelerates Alpha Tau's cancer therapy development with funding for multiple clinical trials, manufacturing scale-up, and commercialization preparation.
This strategic partnership between Oramed and Alpha Tau brings together two companies focused on innovative therapeutic delivery systems, albeit through different technological approaches. Alpha Tau's Alpha DaRT technology represents a specialized approach to cancer treatment that utilizes targeted alpha radiation therapy delivered precisely to tumor sites.
The timing of this investment is strategically significant as Alpha Tau is currently conducting four parallel clinical trials in the United States across multiple cancer indications. The company is simultaneously expanding trials into multiple internal organs while scaling up manufacturing capacity and preparing for potential commercialization.
This capital infusion and strategic support comes at a critical development phase for Alpha Tau's technology platform. Clinical trials represent the essential validation stage for novel cancer therapies, and conducting multiple parallel trials requires substantial resources. With Oramed's capital markets expertise and strategic guidance, Alpha Tau may be better positioned to navigate the complex pathway from clinical development to potential commercialization.
Both delivery technologies share a common philosophy of improving therapeutic delivery - Oramed through converting injectable drugs to oral formulations, and Alpha Tau through precise delivery of radiation therapy to tumor sites while potentially minimizing damage to surrounding tissues. This conceptual alignment suggests a thoughtful strategic partnership rather than merely a financial investment.
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology
Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts
Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology
As part of this collaboration, the parties have entered into a comprehensive three-year service agreement whereby Oramed will provide Alpha Tau with investor and shareholder outreach, business strategic guidance, and capital markets expertise. This strategic investment aligns with Oramed's growth strategy to expand its footprint in innovative therapeutic delivery technologies, enabling Oramed to contribute to Alpha Tau's strategic direction while supporting its market presence and accelerating its path to commercialization. Additionally, Oramed will take an active governance role with the appointment of two directors to Alpha Tau's Board of Directors.
Oramed CEO Nadav Kidron commented, "This strategic alliance with Alpha Tau represents an exceptional opportunity for Oramed to apply our capital markets and business development expertise in supporting what we believe is a truly groundbreaking medical technology. Both companies share a fundamental vision of revolutionizing therapeutic delivery – Oramed through oral administration of injectable drugs and Alpha Tau through precise delivery of radiation therapy to tumor sites. We hold unwavering confidence in the exceptional potential of the Alpha DaRT technology platform and the strategic vision of Alpha Tau's leadership team. We anticipate significant advancements and milestone achievements as they execute their clinical and commercial roadmap."
Alpha Tau CEO Uzi Sofer added, "We are delighted to welcome Oramed as a strategic partner and to leverage their extensive expertise in navigating diverse capital markets channels. There's a natural alignment between our companies' missions to transform how therapies are delivered to patients. This investment comes at the perfect time for Alpha Tau given the rapid expansion of our business activities, including four parallel trial approvals in the
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq: ORMP) (TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. The Company's novel Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption. Oramed has offices in
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT® for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from
Forward-looking statements: This press release contains forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions and include statements on the collaboration between Alpha Tau and the Company. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties in satisfaction of closing conditions for the contemplated transactions, risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in the Company's other filings with the Securities and Exchange Commission, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. These forward-looking statements speak only as of the date hereof. Oramed undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect actual outcomes, unless required by law.
Logo: https://mma.prnewswire.com/media/1724339/3464831/Oramed_Logo.jpg
Company Contact:
+1-844-9-ORAMED
ir@oramed.com
www.oramed.com
View original content:https://www.prnewswire.com/news-releases/oramed-pharmaceuticals-announces-36-9-million-investment-and-strategic-collaboration-with-alpha-tau-medical-302439636.html
SOURCE Oramed Pharmaceuticals Inc.
FAQ
What is the value and terms of Oramed's investment in Alpha Tau Medical (DRTS)?
What services will Oramed provide to Alpha Tau (DRTS) under the strategic collaboration?
How many clinical trials is Alpha Tau (DRTS) currently conducting in the US?
What governance changes will occur at Alpha Tau (DRTS) following Oramed's investment?
